Dr Wierda speaks to ecancer about a recent study presented at ASH 2020 regarding ibrutinib (Ibr) plus venetoclax (Ven) for first-line treatment of chronic lymphocytic leukaemia (CLL)/small lymphocytic lymphoma (SLL).
This study investigates 1-year disease-free survival (DFS) results from the MRD cohort of the phase 2 CAPTIVATE study.
Dr Wierda initially explains what this study is about and says that CAPTIVATE is a multicenter phase 2 study of first-line Ibr Ven with 2 cohorts: Minimal Residual Disease (MRD) and Fixed-Duration (FD).
He says for both cohorts, patients received 3 cycles of Ibr lead-in followed by 12 cycles of combined Ibr Ven. Pts in the MRD cohort were randomised by MRD status to placebo or further treatment.
He then talks about the key results observed in this study and what the future impact of these results can be in the treat meant of CLL and SLL.
This program is funded in part via an independent grant from AbbVie. ecancer is editorially independent and there is no influence over content.